CSL's Seqirus Reveals 19.8% Efficacy of Cell-Based Influenza Vaccines for 2023/24 Season
- CSL Seqirus reports a 19.8% higher effectiveness of cell-based influenza vaccines compared to egg-based vaccines in real-world studies.
- The findings emphasize the importance of cell-based vaccines in public health and influenza prevention strategies for vulnerable populations.
- CSL Seqirus's research reinforces its leadership in vaccine innovation and its role in shaping future public health policies.
CSL Seqirus Unveils Efficacy of Cell-Based Influenza Vaccines
CSL Seqirus, a prominent division of CSL Limited, recently releases significant findings from a real-world evidence study that highlights the effectiveness of cell-based quadrivalent influenza vaccines (QIVc) in the 2023/24 U.S. flu season. The study demonstrates a 19.8% relative vaccine effectiveness (rVE) compared to standard egg-based quadrivalent vaccines (QIVe) in preventing test-confirmed influenza among individuals aged six months to 64 years. With a robust analysis of data from over 106,000 vaccinated patients, the results underscore the advantages of cell-based vaccines across various demographic groups, including pediatric, adult, outpatient, and high-risk populations.
The implications of this research are particularly significant given the context of the previous flu season, which saw a concerning spike in pediatric death rates—the highest since the 2009 pandemic. Dr. Gregg Sylvester, Chief Health Officer at CSL Seqirus, emphasizes that the clinical benefits showcased by cell-based vaccines are not just statistical milestones; they represent a vital strategy for public health in the upcoming flu season. The study, published in the journal Infectious Diseases and Therapy and presented at the IDWeek annual meeting in Atlanta, reflects the ongoing commitment to enhancing the standard of care for influenza prevention, especially in light of the health challenges posed by influenza.
This study marks the fifth consecutive season in which retrospective test-negative studies affirm the superior protection offered by cell-based influenza vaccines over their egg-based counterparts. The comprehensive nature of the data, linked from electronic health records, medical claims, and laboratory tests, reinforces the validity of the findings. As the flu season approaches, the results not only strengthen the case for adopting cell-based vaccines more broadly but also highlight the critical role of effective vaccination strategies in mitigating influenza's impact on vulnerable populations. The need for enhanced vaccination approaches is underscored, particularly as communities prepare for potential health crises during the flu season.
Strengthening Public Health Through Vaccine Innovation
Related Cashu News

Lockheed Martin Advances AI, Autonomy, and Space Exploration for Enhanced Military Operations and Safety
Lockheed Martin (Ticker: LMT) is making significant strides in integrating artificial intelligence and autonomy to enhance the efficiency and safety of military operations. The company focuses on deve…

AeroVironment Reports 133% Revenue Growth Amid Rising Military Demand for UAVs
AeroVironment (Ticker: AVAV) has emerged as a leader in the unmanned aerial vehicle (UAV) industry, particularly amidst a heightened global focus on defense technologies. The company has achieved subs…

AZZ Inc. Earnings Report Could Impact Stock Volatility and Dividend Investor Sentiment
AZZ Inc. (Ticker: AZZ) positions itself strongly in the industrial sector with its upcoming earnings report, reflecting its financial health and dividend strategy. Scheduled for release on July 8, the…

Astronics Signs Long-Term Deal with Vertical Aerospace for Valo eVTOL Power Systems
In late June 2026, Vertical Aerospace establishes a long-term agreement with Astronics Corporation (Ticker: ATRO) to supply the low-voltage power distribution system for its Valo eVTOL aircraft. This…

